- Home
- ADIL vs ALBT Comparison
ADIL vs ALBT Comparison
Compare ADIL & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- ALBT
- Stock Information
- Founded
- ADIL 2010
- ALBT 2014
- Country
- ADIL United States
- ALBT United States
- Employees
- ADIL N/A
- ALBT N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADIL Health Care
- ALBT Health Care
- Exchange
- ADIL Nasdaq
- ALBT Nasdaq
- Market Cap
- ADIL 7.6M
- ALBT 7.4M
- IPO Year
- ADIL 2018
- ALBT N/A
- Fundamental
- Price
- ADIL $0.38
- ALBT $2.22
- Analyst Decision
- ADIL Strong Buy
- ALBT
- Analyst Count
- ADIL 1
- ALBT 0
- Target Price
- ADIL $8.00
- ALBT N/A
- AVG Volume (30 Days)
- ADIL 4.2M
- ALBT 2.0M
- Earning Date
- ADIL 08-19-2025
- ALBT 08-18-2025
- Dividend Yield
- ADIL N/A
- ALBT N/A
- EPS Growth
- ADIL N/A
- ALBT N/A
- EPS
- ADIL N/A
- ALBT N/A
- Revenue
- ADIL N/A
- ALBT $807,235.00
- Revenue This Year
- ADIL N/A
- ALBT N/A
- Revenue Next Year
- ADIL N/A
- ALBT N/A
- P/E Ratio
- ADIL N/A
- ALBT N/A
- Revenue Growth
- ADIL N/A
- ALBT N/A
- 52 Week Low
- ADIL $0.22
- ALBT $1.87
- 52 Week High
- ADIL $1.30
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- ADIL 43.03
- ALBT 44.45
- Support Level
- ADIL $0.39
- ALBT $1.87
- Resistance Level
- ADIL $0.46
- ALBT $4.74
- Average True Range (ATR)
- ADIL 0.08
- ALBT 0.37
- MACD
- ADIL -0.01
- ALBT 0.03
- Stochastic Oscillator
- ADIL 7.29
- ALBT 12.20
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.